Affordable Access

Publisher Website

Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.

Authors
Type
Published Article
Journal
SpringerPlus
2193-1801
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
4
Pages
638–638
Identifiers
DOI: 10.1186/s40064-015-1441-5
PMID: 26543772
Source
Medline
Keywords
  • Dapsone
  • Erlotinib
  • Glioblastoma
  • Interleukin-8
  • Neutrophils
  • Non-Small Cell Lung Cancer
  • Ovarian Cancer
  • Pancreas Cancer
  • Quality Of Life
  • Rash

Abstract

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments